| Literature DB >> 31799309 |
Yun-Feng Shi1, Yu-Kai Wang1, Yan-Hong Wang1, Hui Liu1, Xiao-Han Shi1, Xiao-Jie Li2, Ben-Quan Wu1.
Abstract
BACKGROUND: Klebsiella pneumoniae (K. pneumoniae) used to affect mainly people with compromised immunity or weakened by other infections, but recent emergence of hypervirulent strains has increased infections even in healthy individuals. These infections include liver abscess, pneumonia, bacteremia, meningitis, necrotizing fasciitis, and endophthalmitis. Although metastatic infection by hypervirulent K. pneumoniae (hvKP) is increasingly recognized, co-infection with Cryptococcus neoformans (C. neoformans) meningitis in immunocompetent hosts is rare but fatal. So, it is necessary to determine the risk factors, complications, and comorbidity of this disease. CASEEntities:
Keywords: Case report; Comorbidity; Cryptococcus neoformans meningitis; Hypervirulent Klebsiella pneumoniae; Metastatic infection
Year: 2019 PMID: 31799309 PMCID: PMC6887595 DOI: 10.12998/wjcc.v7.i22.3812
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.337
Resistance profiles and minimum inhibitory concentrations for Klebsiella pneumoniae from blood culture
| Ampicillin | R | ≥ 32 |
| Cefazolin | S | ≤ 4 |
| Ceftazidime | S | ≤ 1 |
| Ceftriaxone | S | ≤ 1 |
| Cefepime | S | ≤ 1 |
| Aztreonam | S | ≤ 1 |
| Imipenem | S | ≤ 1 |
| Ertapenem | S | ≤ 0.5 |
| Amoxicillin/clavulanate | R | UD |
| Piperacillin/tazobactam | S | ≤ 4 |
| Ciprofloxacin | S | ≤ 0.25 |
| Levofloxacin | S | ≤ 0.25 |
| Tobramycin | S | ≤ 1 |
| Gentamicin | S | ≤ 1 |
| Amikacin | S | ≤ 2 |
| Cefotiam | S | UD |
| Cefotetan | S | ≤ 4 |
| Latamoxef | S | UD |
| Cefoperazone/sulbactam | S | ≤ 4 |
| Ampicillin/sulbactam | S | 4 |
| SMZCo | S | ≤ 20 |
| Macrodantin | I | 64 |
| Moxifloxacin | S | ≤ 0.25 |
| ESBL detection | Negative | |
Results from Sun Yat-Sen University Cancer Center. Reported day before admission to Medical Intensive Care Unit of The Third Affiliated Hospital of Sun Yat-Sen University. ESBL: Extended-spectrum β-lactamase; I: Intermediate; MIC: Minimum inhibitory concentration; R: Resistant; S: Sensitive; UD: Undetected; SMZCo: Compound sulfamethoxazole.
Figure 1CT tomography scan at admission and 10 d later. A, B: Axial CT images: lung window setting (A) and mediastinal window setting (B) (slice thickness 3 mm) showed a 25 mm × 27 mm, round, thick-walled cavity in the right upper lobe. C, D: Axial CT images: Lung window setting (C), and mediastinal window setting (D) (slice thickness 3 mm) showed that the thick-walled cavity had been absorbed to a 21 mm × 21 mm, thin-walled cavity after treatment for 10 d. CT: Computed tomography.
Figure 2Body temperature and antibiotic use during hospitalization. Antibiotic use: imipenem-cilastatin sodium 2 g every 8 hr (days 1-11) and 1 g every 6 hr (days 12-16), tigecycline 0.1 g every 12 hr (days 4-16), voriconazole 0.2 g every 12 hr (days 1-11 and 12-16), meropenem 2 g every 8 hr + 5-fluorocytosine 1.5 g every 6 hr + fluconazole 0.4 g every 12 hr (days 16-18).
Figure 3Change in white blood cell count and neutrophil predominance during hospitalization.
Figure 4Change in C-creative protein and procalcitonin during hospitalization.
Figure 5Axial unenhanced computed tomography scan of the head. A: Axial unenhanced computed tomography scan of the head showed marked dilatation of the occipital horn of the lateral ventricles and third ventricles; B: Marked dilatation of the bilateral ventricle.
Resistance profiles and minimum inhibitory concentrations for Klebsiella pneumoniae from cerebrospinal fluid culture
| Ampicillin | R | 16 |
| Piperacillin | S | ≤ 16 |
| Cefazolin | S | ≤ 8 |
| Cefoxitin | S | ≤ 8 |
| Cefuroxime | S | ≤ 4 |
| Cefotaxime | S | ≤ 2 |
| Ceftazidime | S | ≤ 1 |
| Ceftriaxone | S | ≤ 8 |
| Cefepime | S | ≤ 8 |
| Aztreonam | S | ≤ 8 |
| Imipenem | S | ≤ 1 |
| Meropenem | S | ≤ 1 |
| Ertapenem | S | ≤ 2 |
| Amoxicillin/clavulanate | S | ≤ 8/4 |
| Piperacillin/tazobactam | S | ≤ 16 |
| Ticarcillin/clavulanate | S | ≤ 16 |
| Ciprofloxacin | S | ≤ 1 |
| Levofloxacin | S | ≤ 2 |
| Tobramycin | S | ≤ 4 |
| Gentamicin | S | ≤ 4 |
| Amikacin | S | ≤ 8 |
| Tetracycline | S | ≤ 4 |
| Trimethoprim/sulfanilamide | S | ≤ 2/38 |
| Cefotaxime/clavulanate | S | ≤ 0.5 |
| Ceftazidime/clavulanate | S | ≤ 0.25 |
Results from the Third Affiliated Hospital of Sun Yat-Sen University. Report date: 1 d after death. MIC: Minimum inhibitory concentration; R: Resistant; S: Sensitive.
Resistance profiles and minimum inhibitory concentrations for Klebsiella pneumoniae from sputum culture
| Ampicillin | R | > 32 |
| Cefazolin | S | 2 |
| Cefoxitin | S | ≤ 2 |
| Cefuroxime | S | 4 |
| Cefotaxime | S | ≤ 0.5 |
| Ceftazidime | S | ≤ 1 |
| Cefepime | S | ≤ 1 |
| Imipenem | S | ≤ 0.5 |
| Piperacillin/tazobactam | I | 32 |
Results from the Third Affiliated Hospital of Sun Yat-Sen University. Report date: 3 d after death. MIC: Minimum inhibitory concentration; R: Resistant; S: Sensitive; I: Intermediate.